Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Merle Foster who wrote (124)	7/19/1998 11:49:00 AM
From: Thomas Kirwin	Respond to of 422

Sidney, The answer is provided by Mr. Gallup in his recent letter to shareholders for July '98. Don't let your patience run out now after four (4) years. immucor.com This is a powerful statement by Mr. Gallup: "While our 1998 fiscal results are not yet final, we finished the year with strong growth in sales. Bear in mind that this growth took place without our new instrument product line even being available for sale in the US! That's why, in our new fiscal year, we're excited about the potential for solid, double-digit growth-not just in revenue, but in earnings, as well." Additionally, here are two projections regarding sales and revenues from the Yahoo! Immucor Message Board: Earnings and Profit technetx Jul 18 1998 5:35PM EDT I agree , earnings will increase significantly, especially the quarter reported in January. Rosys, Dias, ABS and I-Trac sales will all be working for BLud. Very hard to predict earnings now. The selling price for the ABS is between $80,000 -110,000. There will be liberal discounts IMO. The reagents are the real money makers. Not every account will be a new account so to include a new 50K reagent trail with each ABS placement is not totally accurate. Some of these accounts have already been using reagents with the older techniques, probably close to 50K per year in reagents (I think the ABS does use slightly more reagents...not sure) Also, I think we will be in the 20's long before next July. Re: Jerboal alexporterIs1 Jul 17 1998 5:02PM EDT My research indicates that Immucor's cost for each ABS 2000 is 40 K. This means we are looking at 60 - 70 K profit per machine. Add that to a reagent trail of nearly 50 K per year. That's 110 K or .013 per share per ABS 2000. Multiply that by Gallup's conservative 1 per week for 6 months 2 per week after that and we get 1.01 per share. Add in Roysis and non ABS 2000 reagent sales and we are looking REAL GOOD. I think we may be on to something here. Regards, Tom

To: Sidney Merle Foster who wrote (124)	8/7/1998 6:57:00 AM
From: Thomas Kirwin	Respond to of 422

Media/Investor Kit - ABS2000 FDA Press Release FDA Clears Immucor to Market ABS2000 First Fully Automated Blood Bank System Increases Safety and Productivity (Norcross, Georgia - July 6, 1998) - Immucor, Inc. (NASDAQ: BLUD), Announced today that the U.S. Food and Drug Administration (FDA) has given clearance for the Georgia-based company to market its ABS2000, the first fully automated blood bank system, in the United States. Benefits of totally automating routine blood lab tests are increased efficacy, improved productivity resulting in economic advantages, and greater confidence in test results. The ABS2000 reduces standard serology tests from 23 manual tasks to three steps; 1) load samples; 2) choose the assay; and 3) walk-away. "ABS2000 represents an excellent opportunity to dramatically change routine hospital transfusion laboratory testing as we know it, and solidifies our position as a company with solutions for this industry," said Edward L. Gallup, president and CEO of Immucor. The ABS2000 currently provides more than 20,000 patient test results monthly in Europe and Canada. Clinical trials were performed at sites across the U.S. including large university hospitals, reference laboratories, donor centers, and community hospitals. "We look forward to integrating the ABS2000's walk away features into our workflow, saving laboratory technologist time for more important tasks," said Dr. S. Gerald Sandler, professor of Medicine and Pathology and director of Blood Bank and Donor Service, at Georgetown University Medical Center in Washington, D.C., which serves as a clinical trial site for the system. With this fully automated system, Immucor closes the loop in the administration of blood, and continues toward its goal of making blood compatibility testing procedures faster, easier, and more efficient. The ABS2000 system improves quality assurance, solves staffing problems, and minimizes training concerns; reduces sample handling and exposure to infectious agents; improves data management; reduces risk from human error; eliminates subjectivity from interpreting results; increases accuracy; and brings additional safety for patients. There are more than 2500 facilities in the United States that can benefit from the quality and productivity improvements provided by the ABS2000 system. With no competition in automation for blood banks, Immucor has a distinct competitive advantage in the hospital transfusion service market, and expects to have the first ABS2000 systems installed within the next 60 days. Founded in 1982, Immucor, which was originally a producer of blood bank reagents for manual testing, has moved to a leading role as a supplier of integrated systems (instruments, software, disposables and reagents) to hospitals, laboratories, and blood donor centers that automate manual testing procedures. For product information, visit the website at immucor.com or call 1-800-829-2553, extension 3.